1. Fox, RJ, Miller, DH, Phillips, JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012; 367: 1087–1097.
Google Scholar | Crossref | Medline | ISI2. Gold, R, Kappos, L, Arnold, DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012; 367: 1098–1107.
Google Scholar | Crossref | Medline | ISI3. Kappos, L, Radue, EW, O'Connor, P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401. 2010/01/22.
Google Scholar | Crossref | Medline | ISI4. Cohen, JA, Barkhof, F, Comi, G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415. 2010/01/22.
Google Scholar | Crossref | Medline | ISI5. Braune, S, Grimm, S, van Hövell, P, et al. Comparative effectiveness of delayed-release dimethyl fumarate versus interferon, glatiramer acetate, teriflunomide, or fingolimod: results from the German NeuroTransData registry. J Neurol 2018; 265: 2980–2992. 2018/10/18.
Google Scholar | Crossref | Medline6. Vollmer, B, Ontaneda, D, Bandyopadhyay, A, et al. Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. Neurol Clin Pract 2018; 8: 292–301. 2018/08/25.
Google Scholar | Crossref | Medline7. Vollmer, B, Ontaneda, D, Harris, H, et al. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. J Neurol Sci 2019; 407: 2019. /10/24.
Google Scholar | Crossref8. Mowry, EM, Bermel, R, Williams, JR, et al. Harnessing real-world data to inform decision-making: Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS). Front Neurol 2020; 632 11. DOI: 10.3389/fneur.2020.00632
Google Scholar | Crossref | Medline9. Novartis . Gilenya (fingolimod) highlights of prescribing information, https://www.novartis.us/sites/www.novartis.us/files/gilenya.pdf (2019, accessed November 6 2020).
Google Scholar10. Biogen Inc . TECFIDERA® (dimethyl fumarate) delayed-release capsules, for oral use, https://www.tecfidera.com/content/dam/commercial/multiple-sclerosis/tecfidera/pat/en_us/pdf/full-prescribing-info.pdf (accessed July 26, 2019.).
Google Scholar11. Van Dyken, P, Lacoste, B. Impact of metabolic syndrome on neuroinflammation and the blood-brain barrier. Front Neurosci 2018; 12: 930. 2019/01/09.
Google Scholar | Crossref | Medline12. Lorefice, L, Frau, J, Coghe, G, et al. Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: a case-control MRI study. Mult Scler Relat Disord 2019; 27: 74–78. 2018/10/22.
Google Scholar | Crossref | Medline13. Kappus, N, Weinstock-Guttman, B, Hagemeier, J, et al. Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016; 87: 181–187. 2015/02/28.
Google Scholar | Medline | ISI14. Jakimovski, D, Gandhi, S, Paunkoski, I, et al. Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study. Eur J Neurol 2019; 26: 87–e88. 2018/08/14.
Google Scholar | Crossref | Medline15. Rao, SM, Galioto, R, Sokolowski, M, et al. Multiple sclerosis performance test: validation of self-administered neuroperformance modules. Eur J Neurol 2020; 27: 878–886. 2020/02/06.
Google Scholar | Crossref | Medline16. Rhodes, JK, Schindler, D, Rao, SM, et al. Multiple sclerosis performance test: technical development and usability. Adv Ther 2019; 36: 1741–1755. 2019/05/06.
Google Scholar | Crossref | Medline17. Rao, SM, Losinski, G, Mourany, L, et al. Processing speed test: validation of a self-administered, iPad®-based tool for screening cognitive dysfunction in a clinic setting. Mult Scler 2017; 23: 1929–1937. 2017/01/13.
Google Scholar | SAGE Journals | ISI18. Learmonth, YC, Dlugonski, DD, Pilutti, LA, et al. The reliability, precision and clinically meaningful change of walking assessments in multiple sclerosis. Mult Scler 2013; 19: 1784–1791. 2013/04/17.
Google Scholar | SAGE Journals | ISI19. Young, PS, Middleton, RG, Vasukutty, NL, et al. Primary and revision THA using a stemless metaphyseal-loading implant above distorted proximal femoral anatomy. Hip Int 2013; 23: 40–45. 2012/12/20.
Google Scholar | SAGE Journals | ISI20. Fisher, E, Kober, T, Tsang, A, et al. Magnetic resonance imaging (MRI) metrics in routine clinical practice: proof of concept in MS PATHS (multiple sclerosis partners advancing technology for health solutions). Neurology 2020; 94: 1356.
Google Scholar21. Learmonth, YC, Motl, RW, Sandroff, BM, et al. Validation of patient determined disease steps (PDDS) scale scores in persons with multiple sclerosis. BMC Neurol 2013; 13: 37. 2013/04/27.
Google Scholar | Crossref | Medline | ISI22. Kuhle, J, Barro, C, Andreasson, U, et al. Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and simoa. Clin Chem Lab Med 2016; 54: 1655–1661. 2016/04/14.
Google Scholar | Crossref | Medline | ISI23. Sotirchos, E, Filippatou, A, Fitzgerald, K, et al. Elevated serum neurofilament light chain is associated with accelerated inner retinal layer thinning in multiple sclerosis. Mult Scler 2019; 25(S2): 274.
Google Scholar24. Hersh, C, Lei, Y, de Moor, C, et al. Multiple sclerosis patients initiating dimethyl fumarate versus fingolimod in the real-world setting have baseline characteristics associated with worse clinical prognosis. Mult Scler 2019; 25(S2): 866–867.
Google Scholar25. Benedict, RH, DeLuca, J, Phillips, G, et al. Validity of the symbol digit modalities test as a cognition performance outcome measure for multiple sclerosis. Mult Scler 2017; 23: 721–733. 2017/02/17.
Google Scholar | SAGE Journals | ISI26. Sanfilipo, MP, Benedict, RH, Weinstock-Guttman, B, et al. Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis. Neurology 2006; 66: 685–692. 2006/03/15.
Google Scholar | Crossref | Medline | ISI27. Rocca, MA, Riccitelli, GC, Meani, A, et al. Cognitive reserve, cognition, and regional brain damage in MS: a 2-year longitudinal study. Mult Scler 2019; 25: 372–381. 2018/01/06.
Google Scholar | SAGE Journals | ISI28. Zivadinov, R, Sepcic, J, Nasuelli, D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001; 70: 773–780. 2001/06/01.
Google Scholar | Crossref | Medline | ISI29. Eijlers, AJC, van Geest, Q, Dekker, I, et al. Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain 2018; 141: 2605–2618. 2018/09/01.
Google Scholar | Medline30. Hersh, C, Lei, Y, de Moor, C, et al. Multiple sclerosis patients initiating dimethyl fumarate versus fingolimod in the real-world setting have baseline characteristics associated with worse clinical prognosis. Mult Scler J 2019; 23: 866–867.
Google Scholar31. Leritz, EC, McGlinchey, RE, Kellison, I, et al. Cardiovascular disease risk factors and cognition in the elderly. Curr Cardiovasc Risk Rep 2011; 5: 407–412. 2011/12/27.
Google Scholar | Crossref | Medline32. Hu, P, Lee, J, Beaumaster, S, et al. Cognitive function and cardiometabolic-inflammatory risk factors among older Indians and Americans. J Am Geriatr Soc 2020; 68: S36–S44. 2020/08/21.
Google Scholar | Crossref | Medline33. Shin, SY, Katz, P, Wallhagen, M, et al. Cognitive impairment in persons with rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1144–1150. 2012/04/17.
Google Scholar | Medline34. Yaffe, K, Bahorik, AL, Hoang, TD, et al. Cardiovascular risk factors and accelerated cognitive decline in midlife: the CARDIA study. Neurology 2020; 95: e839–e846. 2020/07/17.
Google Scholar | Crossref | Medline35. LaRocca, NG, Hudson, LD, Rudick, R, et al. The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. Mult Scler 2018; 24: 1469–1484. 2017/08/12.
Google Scholar | SAGE Journals | ISI36. Delcoigne, B, Manouchehrinia, A, Barro, C, et al. Blood neurofilament light levels segregate treatment effects in multiple sclerosis. Neurology 2020; 94: e1201–e1212. 2020/02/13.
Google Scholar | Crossref | Medline